Previous Close | 0.0800 |
Open | 0.0800 |
Bid | 0.0750 x N/A |
Ask | 0.0800 x N/A |
Day's Range | 0.0750 - 0.0800 |
52 Week Range | 0.0650 - 0.2750 |
Volume | |
Avg. Volume | 759,679 |
Market Cap | 24.041M |
Beta (5Y Monthly) | 1.46 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1000 |
Earnings Date | Jul 15, 2024 - Jul 19, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Announced that its research site, Cedar Clinical Research, has been chosen as one of multiple sites ...
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based novel therapies, is proud to announce that its research site, Cedar Clinical Research ("CCR"), has been chosen as one of multiple sites for Cybin's Phase 3 pivotal, multinational clinical trial of CYB003 for the adjunctive treatment of Major Depressive Disorder ("MDD").
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, provides an update following unauthorized disclosure in an online newspaper which has come to its attention.